Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Investors

Fresenius Investment Highlights

Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management

"We have made a successful start into 2019. All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year. High-quality, yet affordable healthcare for ever more patients worldwide is our commitment. Consistent organic growth and major investments into key growth areas continue to reinforce our delivery of that commitment. Those strong foundations will also ensure the long-term success of our business."
(Stephan Sturm, Chairman of the Management Board)

NEXT EVENT

July 30, 2019 | Bad Homburg, Germany

Conference Call Q2 2019, Fresenius

Import (ICS)

NEXT EVENT

News

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

June 19, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches Neostigmine in prefilled syringes in the U.S.

Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.

June 11, 2019Fresenius Kabi
Brief News
S&P upgrades Fresenius to BBB with stable outlook

Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

May 23, 2019Fresenius

Brief News
Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

May 03, 2019Fresenius Kabi
Fresenius makes solid start to 2019 and confirms Group guidance

May 02, 2019Fresenius

Brief News
Fresenius Kabi launches Glycopyrrolate in prefilled syringes in the U.S.

Glycopyrrolate is now available in the company’s Simplist™ ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio. It is the first FDA-approved manufacturer-supplied ready-to-administer prefilled syringe for this medication in the U.S.

April 30, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches Adenosine in prefilled syringes in the U.S.

Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.

April 09, 2019Fresenius Kabi

Brief News
Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

April 03, 2019Fresenius Kabi
Brief News
Fresenius Helios and Marburger Bund agree on collective labor agreement

Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

March 19, 2019Fresenius Helios

Brief News
Fresenius Helios holds topping-out ceremony for new hospital building in Wiesbaden

Fresenius Helios held the topping-out ceremony today for the new main building at Helios HSK hospital in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with almost 100,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, about 1,000 beds, and a design that significantly reduces distances and waiting times for patients. Helios is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2021.

March 15, 2019Fresenius Helios
Fresenius reports 15th consecutive record year – Significant investments into medium-term growth in FY/18 and FY/19 – Healthy medium-term growth targets

February 20, 2019Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Methocarbamol Injection is the newest addition to the company´s anesthesia and analgesia portfolio.

February 12, 2019Fresenius Kabi
Brief News
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira^® is a registered trademark of AbbVie Biotechnology Ltd.

February 01, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

January 29, 2019Fresenius Kabi
Brief News
Fresenius Vamed adds new resort to network in Austria

VAMED Vitality World has taken over operation of a health resort in Austria’s Styria state. Operating under the new name of Spa Resort Styria in the town of Bad Waltersdorf, near Graz, the resort will offer health tourism for adults. Fresenius Vamed is the market leader in Austria, with about 3.2 million annual visitors to the company’s eight thermal spas and health resorts.

January 14, 2019Fresenius Vamed

Fresenius successfully places €1.0 billion in notes

Fresenius today successfully placed notes in two tranches with an aggregate volume of €1.0 billion.
January 10, 2019Fresenius
Brief News
Fresenius wins award for compensatory time account calculator

Fresenius has been awarded the HR Excellence Award 2018 in the Compensation & Benefits category for the global healthcare group’s compensatory time account calculator. This calculator enables employees to quickly and transparently access information on time off that they have banked, options to take leave for continuing education or to care for family members, and possible early retirement. The HR Excellence Awards have been presented by Human Resources Manager magazine since 2012 to recognize outstanding projects in personnel management.

December 14, 2018Fresenius

Brief News
Fresenius Kabi launches Omegaven® in the U.S.

Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.

December 10, 2018Fresenius Kabi
Brief News
PWC proposed as auditor for 2020

The Supervisory Board of Fresenius SE & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020. The shareholders will decide on the appointment at the Annual General Meeting in 2020. New regulations provide for a regular rotation of the auditor, so Fresenius was not able to extend the existing mandate of KPMG AG Wirtschaftsprüfungsgesellschaft.

December 10, 2018Fresenius

Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

December 06, 2018Fresenius
Brief News
Fresenius Kabi receives FDA Drug Shortage Assistance Award

Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA). The FDA recognized the role Fresenius Kabi played in helping mitigate a shortage of IV saline, specifically Sodium Chloride Injection USP, 0.9% in bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria. The hurricane devastated Puerto Rico, where many companies produce medicines for U.S. hospitals.

December 03, 2018Fresenius Kabi

Brief News
Fresenius Vamed wins awards for spa and wellness facilities

VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2018” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Villas, Aqua Dome Therme Längenfeld, Therme Laa Hotel & Spa, all in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.

November 26, 2018Fresenius Vamed
Brief News
Fresenius training programs among the best in Germany

A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.

November 19, 2018Fresenius

Fresenius in Q3/18 with continued strong Group earnings growth in constant currency

October 30, 2018Fresenius
Brief News
Fresenius Helios acquires private hospital operator in Colombia, expanding presence in Latin America

Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.

October 30, 2018Fresenius Helios

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Arsenic Trioxide Injection is the newest addition to the company’s oncology portfolio.

October 26, 2018Fresenius Kabi
Brief News
Fresenius Kabi launches IV drug in the US

Fresenius Kabi HYDROmorphone Hydrochloride injection is a new offering for the company, expanding its analgesia and anesthesia portfolio. It is available in six single-dose vial presentations.

October 24, 2018Fresenius Kabi

Brief News
Fresenius Kabi launches Palonosetron in prefilled syringe in the U.S.

Palonosetron Hydrochloride Injection is now available in the U.S. and is the newest product in the company’s Simplist™ prefilled syringe portfolio. It is an antiemetic used to manage chemotherapy-induced nausea and vomiting. Fresenius Kabi is the first company to offer U.S. customers Palonosetron Hydrochloride in a ready-to-administer syringe.

October 22, 2018Fresenius Kabi
Brief News
Fresenius Kabi launches Heparin in freeflex® container in the U.S.

Fresenius Kabi has launched Heparin Sodium injection in ready-to-administer non-DEHP freeflex^® bags, expanding the company’s critical care portfolio. Fresenius Kabi offers a comprehensive portfolio of Heparin Sodium in the U.S. with multiple vial presentations, a pre-filled syringe and bag presentations.

October 19, 2018Fresenius Kabi

Fresenius Kabi reaches a global agreement with AbbVie

October 18, 2018Fresenius Kabi

Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

I am a private investor I am an institutional investor

Title *

First name * Please enter your first name.

Last name * Please enter your last name.

Company * Please enter your company.

Department * Please enter your department.

Job function *

Please enter your function.

Street / Number * Please enter your street.

Postal Code / City * Please enter your postal code and city.

Country *

E-mail * Please enter your e-mail address.

Telephone number

All fields marked with * are required.

Please send me via email

Fresenius Brief News German English

Fresenius Investor News German English

Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us